LYMPHOMA NON-HODGKIN

This study tests different COVID-19 booster vaccines in 960 immunocompromised people, including those with HIV, organ transplants, or blood cancers. The goal is to find which booster schedule gives the strongest and safest immune response. Results will help doctors protect these …

This early-phase study tests a new drug called JNJ-88998377 in about 58 people with B-cell non-Hodgkin's lymphoma that has returned or not responded to prior treatments. The main goal is to check the drug's safety and find the best dose for future studies. Participants will be cl…

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It is for those who completed an earlier study and are still benefiting from the treatment. Participants will receiv…

This early-stage study tests a new drug combination (JNJ-80948543 plus JNJ-75348780) in 19 adults with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to at least two prior treatments. The main goals are to find the safest dose an…

This early-phase study tests a new treatment for people with relapsed lymphoma tied to the Epstein-Barr virus. The therapy uses the patient's own immune cells, modified to resist a substance tumors use to hide. The goal is to find a safe dose and see if these cells can shrink tum…

This study tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor for people with blood cancers like leukemia and lymphoma. The goal was to see how many patients survived and had successful engraftment by 100 days and one year after transp…

This study tests a treatment called JCAR017, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with a type of slow-growing lymphoma (follicular or marginal zone) that has come back or not responded to prior treatments. The…

This study tests an experimental pill, CC-99282, in people with non-Hodgkin lymphoma whose cancer has returned or not responded to prior treatments. The main goals are to check the drug's safety and find the best dose, both when used alone and with other lymphoma medicines. About…

This study tests a two-step stem cell transplant for people with high-risk non-Hodgkin's lymphoma. First, patients receive their own stem cells, followed by a donor transplant to boost long-term disease control. The trial includes 18 adults aged 18 to 70 with relapsed or hard-to-…

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find the safest dose and to see if the drug can shri…

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers or graft-versus-host disease who completed earlier ibrutinib trials and are still seeing benefits. Participants continue their treatment while researchers collect long-term safety informa…

This study tests a new drug, englumafusp alfa, combined with other treatments (obinutuzumab and glofitamab) in about 500 adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior therapy. The goal is to see if the combination is safe and can shrink…

This early-stage study tests an experimental drug, JNJ-80948543, that helps the body's immune T-cells attack cancer cells. It is for people with certain types of blood cancer (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have not responded to other treatments. The m…

This early-stage study tests a new drug (JNJ-87801493) combined with immune-activating therapies for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goals are to check safety and find the best dose. About 70 participants wil…

This early-phase study tests an experimental therapy called NKX019, made from donor immune cells (natural killer cells) engineered to target and kill cancer cells. It is for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to othe…

This study is testing a new cell therapy for people with Hodgkin's or Non-Hodgkin's lymphoma that has come back or hasn't responded to other treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back. The main go…

This study tests a new way to calculate the dose of the chemotherapy drug melphalan for lymphoma patients getting a stem cell transplant. Instead of a standard dose based on height and weight, researchers use a model that considers how previous patients processed the drug. The go…

This study tests whether siltuximab can lessen the severity of cytokine release syndrome (CRS) and nerve-related side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma, multiple myeloma, and leukemia. About 30 participants will receive silt…

This study tests a program that combines mindfulness and music therapy, delivered through an app or website, for people undergoing a stem cell transplant. The goal is to see if it helps improve quality of life and reduce symptoms like pain. About 60 adults with certain blood canc…

This study collects blood and saliva samples from people with cancer and their family members to build a DNA bank. Researchers will use these samples to study how genes may increase the risk of developing certain cancers. The goal is to better understand inherited cancer tendenci…

This study follows about 50 people who have already received an experimental CAR T cell therapy for certain types of lymphoma. The goal is to track any long-term side effects and survival for up to 15 years after treatment. No new study drug is given, but participants may receive…

This study follows people with different cancers who have already received treatment in an earlier study. The main goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.

This study follows about 150 people who have already received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to track any long-term side effects for up to 15 years after treatment. No new treatments are given—just regular check-ups to monitor safety…

This study is building a large group of 21,000 people newly diagnosed with non-Hodgkin lymphoma to track their health over time. Researchers will look at medical history, lifestyle, genetics, and treatments to find out what affects survival, side effects, and quality of life. The…